: known , she was chosen by the American Society of Nephrology for selected presentations about PBI-1402 in its 42nd Annual Meeting & Scientific Exposition, from 27 October to 1 November 2009,. In San Diego, California ProMetic orally active lead compound for the treatment of anemia, PBI-1402 is in clinical development for the treatment of anemia caused by chemotherapy and / or induces in the context of cancer . A phase Ib / II trial showed a significant increase in hemoglobin and red blood cells and a reduction the need for blood transfusion in patients with CIA.. Report the results of PBI-1402 data at upcoming annual meeting of the American Society of Nephrology – ProMetic Life Sciences Inc.
Source ProMetic Life Sciences Inc.at home,ehealth ‘devices enable the follow patient diseases From HomeNew York Times: ‘older[ T] housands are of seriously ill patients on computerized health depend trackers to help keep them safe at home, researchers say devices like this can motivate. Patient follow with chronic diseases such as heart or lung disease, advanced diabetes or depression advice from their doctors and nurses and to take part in their own care..State Comptroller Dan Hynes and several lawmakers by which audit be planned criticize Blagojevich on attempt implement a proposal Family Care government state subsidized care program. Said: ‘This said: ‘This is appalling and inexcusably ‘and added, ‘providers of health services was a as a result of the ongoing mismanagement of of the program. ‘.
The researchers showed that action in breast cancer cells, an inflammatory protein known as AF W and the estrogen receptor collectively, the expression of the expression of the transporter gene? And were to show in on or off. We found that the estrogen receptor to the promoter of this gene is adjusted, say Frasor. There, the ER NF? be recruited around its own response element. .